{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:52:25Z","timestamp":1773939145027,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PEF2018-004607-A"],"award-info":[{"award-number":["PEF2018-004607-A"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejphar.2025.178484","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:43:46Z","timestamp":1766130226000},"page":"178484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Functional in vitro assessment of the HER2 Ile655Val variant on trastuzumab-induced cardiotoxicity in human cardiomyocytes"],"prefix":"10.1016","volume":"1012","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-6296","authenticated-orcid":false,"given":"Ana","family":"Pozo-Agundo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8959-4797","authenticated-orcid":false,"given":"Sonia","family":"Garc\u00eda-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3963-6546","authenticated-orcid":false,"given":"Alba","family":"Ant\u00fanez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Chica-Redecillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina Beatriz","family":"Cejas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2929-5100","authenticated-orcid":false,"given":"Davi","family":"Lyra-Leite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Porras-Quesada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"G\u00f3mez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benito","family":"Mir\u00f3n-Pozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5492-9355","authenticated-orcid":false,"given":"Mar\u00eda Jes\u00fas","family":"\u00c1lvarez-Cubero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W.","family":"Burridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Javier","family":"Mart\u00ednez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3339-239X","authenticated-orcid":false,"given":"Cristina Luc\u00eda","family":"D\u00e1vila-Fajardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178484_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaccao.2024.12.007","article-title":"Risk stratification for trastuzumab-induced cardiac dysfunction and potential implications for surveillance","volume":"7","author":"Ali","year":"2025","journal-title":"JACC CARDIOONCOLOGY"},{"key":"10.1016\/j.ejphar.2025.178484_bib2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s100380200019","article-title":"Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer","volume":"47","author":"Ameyaw","year":"2002","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ejphar.2025.178484_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10549-019-05453-z","article-title":"A pooled analysis of the cardiac events in the trastuzumab adjuvant trials","volume":"179","author":"Azambuja","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2025.178484_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102853","article-title":"Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer","volume":"132","author":"Bartsch","year":"2025","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejphar.2025.178484_bib5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/annonc\/mdm181","article-title":"Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity","volume":"18","author":"Beauclair","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejphar.2025.178484_bib6","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nmeth.2999","article-title":"Chemically defined and small molecule-based generation of human cardiomyocytes","volume":"11","author":"Burridge","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ejphar.2025.178484_bib7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.178484_bib8","first-page":"56","article-title":"Use of anthracyclines and trastuzumab for breast cancer in women with and without a history of cardiovascular disease in Sweden: a national cross-sectional study","volume":"11","author":"Carreira","year":"2025","journal-title":"Cardio-Oncol. Lond. Engl."},{"key":"10.1016\/j.ejphar.2025.178484_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.redox.2015.12.008","article-title":"The bioenergetic health index is a sensitive measure of oxidative stress in human monocytes","volume":"8","author":"Chacko","year":"2016","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejphar.2025.178484_bib10","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41401-024-01397-3","article-title":"A recombinant fragment antigen-binding (Fab) of trastuzumab displays low cytotoxic profile in adult human cardiomyocytes: first evidence and the key implication of Fc\u03b3RIIA receptor","volume":"46","author":"De Bartolo","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2025.178484_bib11","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/ncomms2236","article-title":"Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolism","volume":"3","author":"Ding","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178484_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114160","article-title":"Independent compartmentalization of functional, metabolic, and transcriptional maturation of hiPSC-derived cardiomyocytes","volume":"43","author":"Fetterman","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2025.178484_bib13","doi-asserted-by":"crossref","first-page":"15937","DOI":"10.1073\/pnas.252640799","article-title":"A putative molecular-activation switch in the transmembrane domain of erbB2","volume":"99","author":"Fleishman","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2025.178484_bib14","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1161\/CIRCULATIONAHA.118.037357","article-title":"Human-induced pluripotent stem cell model of trastuzumab-induced cardiac dysfunction in patients with breast cancer","volume":"139","author":"Kitani","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.178484_bib15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.toxlet.2018.01.001","article-title":"Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes","volume":"285","author":"Kurokawa","year":"2018","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.ejphar.2025.178484_bib16","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3390\/biomedicines12091970","article-title":"Changes in mitochondrial function and cell death patterns in peripheral blood mononuclear cells during trastuzumab treatment following doxorubicin chemotherapy","volume":"12","author":"Leemasawat","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2025.178484_bib17","first-page":"2569","article-title":"Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab","volume":"33","author":"Lemieux","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejphar.2025.178484_bib18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ijcard.2018.12.049","article-title":"Roles of pharmacogenomics in non-anthracycline antineoplastic-induced cardiovascular toxicities: a systematic review and meta-analysis of genotypes effect","volume":"280","author":"Leong","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178484_bib19","doi-asserted-by":"crossref","DOI":"10.3892\/etm.2021.9904","article-title":"Ginsenoside Rg2 protects cardiomyocytes against trastuzumab-induced toxicity by inducing autophagy","volume":"21","author":"Liu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejphar.2025.178484_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCULATIONAHA.121.055801","article-title":"Identification of drug transporter genomic variants and inhibitors that protect against doxorubicin-induced cardiotoxicity","volume":"145","author":"Magdy","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.178484_bib21","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s10147-025-02727-z","article-title":"Optimal follow-up duration of cardiac function tests in patients treated with trastuzumab: an analysis using the Japanese adverse drug event report (JADER) database","volume":"30","author":"Makihara","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178484_bib22","doi-asserted-by":"crossref","unstructured":"Nakano, M.H., Udagawa, C., Shimo, A., Kojima, Y., Yoshie, R., Zaha, H., Abe, N., Motonari, T., Unesoko, M., Tamura, K., Shimoi, T., Yoshida, M., Yoshida, T., Sakamoto, H., Kato, K., Mushiroda, T., Tsugawa, K., Zembutsu, H., n.d. A genome-wide association study identifies five novel genetic markers for trastuzumab-induced cardiotoxicity in Japanese population 42, 2045\u20132053. https:\/\/doi.org\/10.1248\/BPB.B19-00527.","DOI":"10.1248\/bpb.b19-00527"},{"key":"10.1016\/j.ejphar.2025.178484_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40169-016-0133-2","article-title":"The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC\u2010derived cardiomyocytes","volume":"6","author":"Necela","year":"2017","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejphar.2025.178484_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14174","article-title":"Mitochondrial HER2 stimulates respiration and promotes tumorigenicity","volume":"54","author":"Novotna","year":"2024","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2025.178484_bib25","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/FPC.0000000000000149","article-title":"Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis","volume":"25","author":"Pe\u00f1a","year":"2015","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.ejphar.2025.178484_bib26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10549-013-2587-x","article-title":"Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial","volume":"139","author":"Roca","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2025.178484_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/ars.2016.6677","article-title":"Selective disruption of respiratory supercomplexes as a new strategy to suppress Her2high breast cancer","volume":"26","author":"Rohlenova","year":"2017","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.ejphar.2025.178484_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijcard.2016.09.088","article-title":"Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent","volume":"225","author":"S\u00e1nchez-Ramos","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejphar.2025.178484_bib29","first-page":"378","article-title":"Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. Pharmacogenet","volume":"27","author":"Serie","year":"2017","journal-title":"Genomics"},{"key":"10.1016\/j.ejphar.2025.178484_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2025.178484_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","article-title":"Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer","volume":"18","author":"Tarantini","year":"2012","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ejphar.2025.178484_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-93634-6","article-title":"Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer","volume":"11","author":"Vazdar","year":"2021","journal-title":"Sci. Rep."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925012385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925012385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:34:22Z","timestamp":1773934462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925012385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"alternative-id":["S0014299925012385"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178484","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional in vitro assessment of the HER2 Ile655Val variant on trastuzumab-induced cardiotoxicity in human cardiomyocytes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"178484"}}